Cargando…

Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial

Chronic pain is common and debilitating in cancer survivors. Tibetan herbal pain-relieving plaster is used as an external analgesic to treat musculoskeletal pain in China; however, its safety and efficacy have not been evaluated via clinical trials in cancer survivors. We designed this Phase II rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mingxiao, Baser, Raymond E., Li, Susan Q., Hou, Yen-Nien, Chong, Kamyar, Zhang, Yi Lily, Hoque, Irfan, Bao, Ting, Mao, Jun J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114465/
https://www.ncbi.nlm.nih.gov/pubmed/35600872
http://dx.doi.org/10.3389/fphar.2022.878371
_version_ 1784709780913258496
author Yang, Mingxiao
Baser, Raymond E.
Li, Susan Q.
Hou, Yen-Nien
Chong, Kamyar
Zhang, Yi Lily
Hoque, Irfan
Bao, Ting
Mao, Jun J.
author_facet Yang, Mingxiao
Baser, Raymond E.
Li, Susan Q.
Hou, Yen-Nien
Chong, Kamyar
Zhang, Yi Lily
Hoque, Irfan
Bao, Ting
Mao, Jun J.
author_sort Yang, Mingxiao
collection PubMed
description Chronic pain is common and debilitating in cancer survivors. Tibetan herbal pain-relieving plaster is used as an external analgesic to treat musculoskeletal pain in China; however, its safety and efficacy have not been evaluated via clinical trials in cancer survivors. We designed this Phase II randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04916249) to assess the efficacy and safety of the pain-relieving plaster for temporary pain relief among cancer survivors with chronic musculoskeletal pain. Under ethical approval from the Institutional Review Board at the Memorial Sloan Kettering Cancer Center, we will enroll eligible cancer survivors who have a clinical diagnosis of moderate to severe chronic musculoskeletal pain in this study. We use a central randomization system to allocate the eligible participants to either the treatment or the control group in a 1:1 ratio, with stratification by baseline opioid use. We will instruct the participants to apply the herbal patch (Tibetree Pain-Relieving Plaster, Tibet Cheezheng Tibetan Medicine Co. Ltd., Tibet, China) or placebo patch daily at the focal area with worst pain for 14 consecutive days. Study physician, participant, outcome assessor, and biostatistician are blinded to the group allocation. The primary outcome is pain severity measured by the Brief Pain Inventory on Days 2–7. Secondary outcomes include changes in insomnia, anxiety, depression, fatigue, pressure pain threshold, pain medication use, and global impression of change. We will also monitor the adverse events throughout the study period. Statistical analysis will follow the intention-to-treat principle and linear mixed modeling will be used. With rigorous design and implementation, this randomized, placebo-controlled trial will provide the initial evidence on the efficacy and safety of the pain-relieving plaster for pain relief among cancer survivors with chronic musculoskeletal pain.
format Online
Article
Text
id pubmed-9114465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91144652022-05-19 Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial Yang, Mingxiao Baser, Raymond E. Li, Susan Q. Hou, Yen-Nien Chong, Kamyar Zhang, Yi Lily Hoque, Irfan Bao, Ting Mao, Jun J. Front Pharmacol Pharmacology Chronic pain is common and debilitating in cancer survivors. Tibetan herbal pain-relieving plaster is used as an external analgesic to treat musculoskeletal pain in China; however, its safety and efficacy have not been evaluated via clinical trials in cancer survivors. We designed this Phase II randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04916249) to assess the efficacy and safety of the pain-relieving plaster for temporary pain relief among cancer survivors with chronic musculoskeletal pain. Under ethical approval from the Institutional Review Board at the Memorial Sloan Kettering Cancer Center, we will enroll eligible cancer survivors who have a clinical diagnosis of moderate to severe chronic musculoskeletal pain in this study. We use a central randomization system to allocate the eligible participants to either the treatment or the control group in a 1:1 ratio, with stratification by baseline opioid use. We will instruct the participants to apply the herbal patch (Tibetree Pain-Relieving Plaster, Tibet Cheezheng Tibetan Medicine Co. Ltd., Tibet, China) or placebo patch daily at the focal area with worst pain for 14 consecutive days. Study physician, participant, outcome assessor, and biostatistician are blinded to the group allocation. The primary outcome is pain severity measured by the Brief Pain Inventory on Days 2–7. Secondary outcomes include changes in insomnia, anxiety, depression, fatigue, pressure pain threshold, pain medication use, and global impression of change. We will also monitor the adverse events throughout the study period. Statistical analysis will follow the intention-to-treat principle and linear mixed modeling will be used. With rigorous design and implementation, this randomized, placebo-controlled trial will provide the initial evidence on the efficacy and safety of the pain-relieving plaster for pain relief among cancer survivors with chronic musculoskeletal pain. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9114465/ /pubmed/35600872 http://dx.doi.org/10.3389/fphar.2022.878371 Text en Copyright © 2022 Yang, Baser, Li, Hou, Chong, Zhang, Hoque, Bao and Mao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yang, Mingxiao
Baser, Raymond E.
Li, Susan Q.
Hou, Yen-Nien
Chong, Kamyar
Zhang, Yi Lily
Hoque, Irfan
Bao, Ting
Mao, Jun J.
Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial
title Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial
title_full Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial
title_fullStr Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial
title_full_unstemmed Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial
title_short Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial
title_sort tibetan herbal pain-relieving plaster for chronic musculoskeletal pain among cancer survivors: study protocol of a randomized, double-blind, placebo-controlled trial
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114465/
https://www.ncbi.nlm.nih.gov/pubmed/35600872
http://dx.doi.org/10.3389/fphar.2022.878371
work_keys_str_mv AT yangmingxiao tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT baserraymonde tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT lisusanq tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT houyennien tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT chongkamyar tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT zhangyilily tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT hoqueirfan tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT baoting tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial
AT maojunj tibetanherbalpainrelievingplasterforchronicmusculoskeletalpainamongcancersurvivorsstudyprotocolofarandomizeddoubleblindplacebocontrolledtrial